Loading
A phase 1/2 trial in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer is a phase 1/2, randomised interventional study registered as NCT04172532 by National Cancer Institute (NCI), with a registry enrolment figure of 92 participants, started 2021-01-11 and due to reach its primary completion in 2027-08-01. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Hypofractionated Radiation Therapy; Magnetic Resonance Imaging; Peposertib; Placebo Administration. Conditions listed: Locally Advanced Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8. Primary outcome: Maximum tolerated dose (Phase I); Recommended phase 2 dose (Phase I); Progression-free survival rate (Phase II). Pancreatic eligibility wording from the registry: "* Patients must have pathologically confirmed pancreatic adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), IMRT / IGRT (modern external beam) and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), IMRT / IGRT (modern external beam) and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), IMRT / IGRT (modern external beam) and the tag pancreatic-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/